LON:IMM - Immupharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
GBX 20.45 -0.80 (-3.76 %)
(As of 07/22/2018 04:00 PM ET)
Previous CloseGBX 20.45
Today's RangeGBX 20.30 - GBX 21.10
52-Week RangeGBX 44 - GBX 193.74
Volume591,308 shs
Average Volume817,845 shs
Market Capitalization£174.33 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Immupharma logoImmuPharma plc, a pharmaceutical company, develops drug candidates based on peptide therapeutics to treat serious medical conditions. The company's lead product candidate is the Lupuzor, which is in Phase III clinical trials for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include IPP-204106, an anti-cancer nucleolin antagonis peptide program that has completed Phase I/IIa clinical trials to treat cancer; IPP-102199, which is in pre-clinical development stage to treat severe pain; IPP-201007 that is in early development stage for the treatment of inflammatory and allergic conditions, such as asthma and other respiratory disorders, rheumatoid arthritis, septic shock, and acute pancreatitis; and IPP-203101, a peptide-based antibiotic, which is in pre-clinical development stage for the treatment of lethal infections, including methicillin-resistant staphylococcus aureus and other hospital acquired infections. The company's discovery pipeline includes heterocyclic ureas scaffolds; and peptide to drug converting technology that enhances a peptide's plasma half-life and efficacy. ImmuPharma plc has collaboration arrangements with the Centre National de la Recherché Scientifique; and Institut National de la Sante et de la Recherche Medicale. The company was founded in 1999 and is headquartered in London, the United Kingdom.

Receive IMM News and Ratings via Email

Sign-up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange LON
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolLON:IMM
CUSIPN/A
Phone+44-20-71524080

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-3,507.40%
Return on Equity-101.24%
Return on Assets-86.98%

Miscellaneous

EmployeesN/A
Outstanding Shares129,670,000
Market Cap£174.33

Immupharma (LON:IMM) Frequently Asked Questions

What is Immupharma's stock symbol?

Immupharma trades on the London Stock Exchange (LON) under the ticker symbol "IMM."

What price target have analysts set for IMM?

3 brokerages have issued 1-year target prices for Immupharma's shares. Their forecasts range from GBX 181 to GBX 237. On average, they expect Immupharma's share price to reach GBX 199.67 in the next year. This suggests a possible upside of 876.4% from the stock's current price. View Analyst Ratings for Immupharma.

What is the consensus analysts' recommendation for Immupharma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immupharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Immupharma's key competitors?

Who are Immupharma's key executives?

Immupharma's management team includes the folowing people:
  • Mr. Dimitri F. Dimitriou M.Sc., Co-Founder, CEO & Director (Age 56)
  • Dr. D. Robert Henri Zimmer M.D., Ph.D., Co-Founder, Pres, Chief Scientific Officer & Director (Age 70)
  • Ms. Tracy Weimar BA, MBA, VP of Operations & Fin. and Company Sec.
  • Dr. Jean-Marie Geiger PharmD, MD, Head of Clinical Devel.
  • Mr. Nicholas Peter Kostopoulos, Lupuzor Director of Bus. Devel. - United States

Has Immupharma been receiving favorable news coverage?

News coverage about IMM stock has trended somewhat positive on Sunday, according to Accern. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Immupharma earned a media sentiment score of 0.14 on Accern's scale. They also gave media coverage about the company an impact score of 45.61 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of Immupharma?

Shares of IMM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Immupharma's stock price today?

One share of IMM stock can currently be purchased for approximately GBX 20.45.

How big of a company is Immupharma?

Immupharma has a market capitalization of £174.33 million.

How can I contact Immupharma?

Immupharma's mailing address is 50 Broadway, LONDON, SW1H 0BL, United Kingdom. The company can be reached via phone at +44-20-71524080.


MarketBeat Community Rating for Immupharma (LON IMM)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  186 (Vote Outperform)
Underperform Votes:  78 (Vote Underperform)
Total Votes:  264
MarketBeat's community ratings are surveys of what our community members think about Immupharma and other stocks. Vote "Outperform" if you believe IMM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.